Developer docs
API playgroundTry for free, no card

Search company profiles

ZZ Biotech

Full company profile

uuid000c1bt

Namestring
ZZ Biotech
Legal namestring
ZZ Biotech, LLC
Websiteurl
zzbiotech.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

ZZ Biotech, LLC is a privately held, clinical-stage biotechnology company founded in 2006 and headquartered at 4265 San Felipe St., Suite 1100, Houston, Texas. It was originally positioned around biologic treatments for ischemic stroke and currently operates with a 1–10 employee footprint under CEO Kent Pryor, with Berislav V. Zlokovic listed as co-founder.

The company's core technology is 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease that has been optimized for human therapeutic use. Rather than commercialize directly, ZZ Biotech has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd., positioning the asset in wound-therapy and dermatological applications while ZZ Biotech retains the underlying development activities.

From a business-model perspective, ZZ Biotech is pre-revenue from product sales and is pursuing a licensing/royalty monetization path via the Dermatherix relationship. Its funding history is limited and dated: a $1.0M round in March 2014 led by the National Institutes of Health with Broadview Ventures, and a $6.925M round in 2015 with undisclosed investors. The company also acquired Bioatrix in January 2016 for an undisclosed amount, indicating some inorganic platform activity. Operating geography is the United States, and the firm holds no disclosed institutional investors, parent company, or subsidiary structure.

Short descriptiontext

ZZ Biotech is a privately held, Houston-based clinical-stage biotech developing 3K3A-APC, an engineered variant of human activated protein C, and has licensed its dermatology program to Dermatherix for wound-therapy development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologic therapeutics, protein engineering, wound care therapy, ischemic stroke, clinical stage biotech
Industry2 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Stage Biopharmaceuticals
Social media profiles1 record
Revenue model1 record
1Licensing Royalties
TypeLicensing Royalties
Description

ZZ Biotech has been developing 3K3A-APC and has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd. The company appears to be pre-revenue from product sales and is pursuing a licensing model for its drug development program.

zzbiotech.com
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company focuses on biologic treatments for ischemic stroke and has licensed its 3K3A-APC dermatology program to Dermatherix, Pty Ltd. for wound therapy applications. As a clinical stage biotech, ZZ Biotech monetizes its proprietary engineered protein IP through licensing arrangements rather than direct commercialization.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ZZ Biotech is a biotech company that developed 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company has licensed its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd., while retaining its core development activities.

Product and service1 record
13K3A-APC
CategoryBiologic Therapeutics / Engineered Protein Drug
Description

3K3A-APC is a genetically engineered variant of human activated protein C (APC), a serine protease, optimized for human therapeutic use and being developed for wound therapy and dermatology applications. It is intended for biotech and pharmaceutical partners seeking novel biologic assets for wound care and dermatology pipelines.

Partnership1 partner
1Dermatherix, Pty Ltd.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

ZZ Biotech has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd. Dermatherix is described as a pioneering biotech company dedicated to advancing wound therapies through innovative research. The 3K3A-APC program, which ZZ Biotech had been developing, will be advanced by the team at Dermatherix.

zzbiotech.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers4 records
TypeDirect peer
Description

Clinical-stage company developing CTX stem cell therapy for stroke disability. Comparable to ZZ Biotech as a small clinical-stage biotech in the neuro-regeneration space with a single lead asset and limited headcount.

TypeDirect peer
Description

Clinical-stage regenerative medicine company developing SB623 cell therapy for chronic stroke and traumatic brain injury. Comparable to ZZ Biotech as a small clinical-stage biotech focused on CNS indications with a novel biologic and licensing/partnering strategy.

4Athersys
TypeDirect peer
Description

Clinical-stage biotech developing regenerative therapies for ischemic stroke (MultiStem cell therapy), with parallel programs in wound care/inflammatory conditions. Directly comparable to ZZ Biotech as a small-cap clinical-stage company targeting stroke with a novel biologic modality and seeking partnership-led commercialization.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZZ Biotech

Clinical Stage Biopharmaceuticalszzbiotech.com

ZZ Biotech is a privately held, Houston-based clinical-stage biotech developing 3K3A-APC, an engineered variant of human activated protein C, and has licensed its dermatology program to Dermatherix for wound-therapy development.

What ZZ Biotech does

ZZ Biotech, LLC is a privately held, clinical-stage biotechnology company founded in 2006 and headquartered at 4265 San Felipe St., Suite 1100, Houston, Texas. It was originally positioned around biologic treatments for ischemic stroke and currently operates with a 1–10 employee footprint under CEO Kent Pryor, with Berislav V. Zlokovic listed as co-founder.

The company's core technology is 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease that has been optimized for human therapeutic use. Rather than commercialize directly, ZZ Biotech has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd., positioning the asset in wound-therapy and dermatological applications while ZZ Biotech retains the underlying development activities.

From a business-model perspective, ZZ Biotech is pre-revenue from product sales and is pursuing a licensing/royalty monetization path via the Dermatherix relationship. Its funding history is limited and dated: a $1.0M round in March 2014 led by the National Institutes of Health with Broadview Ventures, and a $6.925M round in 2015 with undisclosed investors. The company also acquired Bioatrix in January 2016 for an undisclosed amount, indicating some inorganic platform activity. Operating geography is the United States, and the firm holds no disclosed institutional investors, parent company, or subsidiary structure.

ZZ Biotech firmographics

Firmographics
Name
ZZ Biotech
Legal name
ZZ Biotech, LLC
Website
https://zzbiotech.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
ZZ Biotech is a privately held, Houston-based clinical-stage biotech developing 3K3A-APC, an engineered variant of human activated protein C, and has licensed its dermatology program to Dermatherix for wound-therapy development.
Ownership category
akta.pro rank

ZZ Biotech industry classification

Industry
Product category
Clinical Stage Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Biologic therapeutics
  • Protein engineering
  • Wound care therapy
  • Ischemic stroke
  • Clinical stage biotech

Where ZZ Biotech is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ZZ Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing Royalties: ZZ Biotech has been developing 3K3A-APC and has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd. The company appears to be pre-revenue from product sales and is pursuing a licensing model for its drug development program.

ZZ Biotech product offering

Product offering

Core offering

ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company focuses on biologic treatments for ischemic stroke and has licensed its 3K3A-APC dermatology program to Dermatherix, Pty Ltd. for wound therapy applications. As a clinical stage biotech, ZZ Biotech monetizes its proprietary engineered protein IP through licensing arrangements rather than direct commercialization.

Product overview

ZZ Biotech is a biotech company that developed 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company has licensed its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd., while retaining its core development activities.

Differentiator

Problem solved

Functional benefit

Products and services

  • 3K3A-APC 3K3A-APC is a genetically engineered variant of human activated protein C (APC), a serine protease, optimized for human therapeutic use and being developed for wound therapy and dermatology applications. It is intended for biotech and pharmaceutical partners seeking novel biologic assets for wound care and dermatology pipelines.

Companies that use ZZ Biotech

Customer profile

Segments1 record

Ideal customer profiles1 record

ZZ Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

ZZ Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Dermatherix, Pty Ltd.coreOEM/ Whitelabel/ Licensing PartnerZZ Biotech has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd. Dermatherix is described as a pioneering biotech company dedicated to advancing wound therapies through innovative research. The 3K3A-APC program, which ZZ Biotech had been developing, will be advanced by the team at Dermatherix.

Recent moves4 records

Expansion highlights3 records

ZZ Biotech competitors and assessment

Company assessment

Peers

Direct peers

  • ReNeuron Group: Clinical-stage company developing CTX stem cell therapy for stroke disability. Comparable to ZZ Biotech as a small clinical-stage biotech in the neuro-regeneration space with a single lead asset and limited headcount.
  • SanBio: Clinical-stage regenerative medicine company developing SB623 cell therapy for chronic stroke and traumatic brain injury. Comparable to ZZ Biotech as a small clinical-stage biotech focused on CNS indications with a novel biologic and licensing/partnering strategy.
  • Athersys: Clinical-stage biotech developing regenerative therapies for ischemic stroke (MultiStem cell therapy), with parallel programs in wound care/inflammatory conditions. Directly comparable to ZZ Biotech as a small-cap clinical-stage company targeting stroke with a novel biologic modality and seeking partnership-led commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

ZZ Biotech social profiles

Digital presence

ZZ Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZZ Biotech leadership team

Management profile

Number of profiles

Profiles2 records

ZZ Biotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZZ Biotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZZ Biotech

What does ZZ Biotech do?

ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company focuses on biologic treatments for ischemic stroke and has licensed its 3K3A-APC dermatology program to Dermatherix, Pty Ltd. for wound therapy applications. As a clinical stage biotech, ZZ Biotech monetizes its proprietary engineered protein IP through licensing arrangements rather than direct commercialization.

Is ZZ Biotech a public or private company?

ZZ Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ZZ Biotech founded?

ZZ Biotech was founded in 2006. It employs 11 to 50 people.

Where is ZZ Biotech based?

ZZ Biotech is headquartered in Houston, United States, in the North America region.

How does ZZ Biotech make money?

One revenue line is on record: licensing Royalties.

Who are ZZ Biotech's main competitors?

BioAxone BioSciences is listed as a peer. Direct peers are ReNeuron Group, SanBio and Athersys.

Does ZZ Biotech have an API?

No public API is recorded for ZZ Biotech.

What industry is ZZ Biotech in?

ZZ Biotech's product category is Clinical Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals